BRD4 is a novel therapeutic target for liver fibrosis

Ning Ding, Nasun Hah, Ruth T. Yu, Mara Sherman, Chris Benner, Mathias Leblanc, Mingxiao He, Christopher Liddle, Michael Downes, Ronald M. Evans

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Liver fibrosis is characterized by the persistent deposition of extracellular matrix components by hepatic stellate cell (HSC)-derived myofibroblasts. It is the histological manifestation of progressive, but reversible wound-healing processes. An unabated fibrotic response results in chronic liver disease and cirrhosis, a pathological precursor of hepatocellular carcinoma. We report here that JQ1, a small molecule inhibitor of bromodomain-containing protein 4(BRD4), a member of bromodomain and extraterminal (BET) proteins, abrogate cytokine-induced activation of HSCs. Cistromic analyses reveal that BRD4 is highly enriched at enhancers associated with genes involved in multiple profibrotic pathways, where BRD4 is colocalized with profibrotic transcription factors. Furthermore, we show that JQ1 is not only protective, but can reverse the fibrotic response in carbon tetrachloride-induced fibrosis in mouse models. Our results implicate that BRD4 can act as a global genomic regulator to direct the fibrotic response through its coordinated regulation of myofibroblast transcription. This suggests BRD4 as a potential therapeutic target for patients with fibrotic complications.

Original languageEnglish (US)
Pages (from-to)15713-15718
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number51
DOIs
StatePublished - Dec 22 2015
Externally publishedYes

Fingerprint

Liver Cirrhosis
Proteins
Myofibroblasts
Therapeutics
Hepatic Stellate Cells
Carbon Tetrachloride
Wound Healing
Extracellular Matrix
Liver Diseases
Hepatocellular Carcinoma
Fibrosis
Chronic Disease
Transcription Factors
Cytokines
Genes

Keywords

  • Antifibrotic therapy
  • BET inhibitor
  • BRD4
  • Hepatic stellate cell
  • Liver fibrosis

ASJC Scopus subject areas

  • General

Cite this

BRD4 is a novel therapeutic target for liver fibrosis. / Ding, Ning; Hah, Nasun; Yu, Ruth T.; Sherman, Mara; Benner, Chris; Leblanc, Mathias; He, Mingxiao; Liddle, Christopher; Downes, Michael; Evans, Ronald M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 51, 22.12.2015, p. 15713-15718.

Research output: Contribution to journalArticle

Ding, N, Hah, N, Yu, RT, Sherman, M, Benner, C, Leblanc, M, He, M, Liddle, C, Downes, M & Evans, RM 2015, 'BRD4 is a novel therapeutic target for liver fibrosis', Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 51, pp. 15713-15718. https://doi.org/10.1073/pnas.1522163112
Ding, Ning ; Hah, Nasun ; Yu, Ruth T. ; Sherman, Mara ; Benner, Chris ; Leblanc, Mathias ; He, Mingxiao ; Liddle, Christopher ; Downes, Michael ; Evans, Ronald M. / BRD4 is a novel therapeutic target for liver fibrosis. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 51. pp. 15713-15718.
@article{5eccd17aaa3b41509b876c4e08c18577,
title = "BRD4 is a novel therapeutic target for liver fibrosis",
abstract = "Liver fibrosis is characterized by the persistent deposition of extracellular matrix components by hepatic stellate cell (HSC)-derived myofibroblasts. It is the histological manifestation of progressive, but reversible wound-healing processes. An unabated fibrotic response results in chronic liver disease and cirrhosis, a pathological precursor of hepatocellular carcinoma. We report here that JQ1, a small molecule inhibitor of bromodomain-containing protein 4(BRD4), a member of bromodomain and extraterminal (BET) proteins, abrogate cytokine-induced activation of HSCs. Cistromic analyses reveal that BRD4 is highly enriched at enhancers associated with genes involved in multiple profibrotic pathways, where BRD4 is colocalized with profibrotic transcription factors. Furthermore, we show that JQ1 is not only protective, but can reverse the fibrotic response in carbon tetrachloride-induced fibrosis in mouse models. Our results implicate that BRD4 can act as a global genomic regulator to direct the fibrotic response through its coordinated regulation of myofibroblast transcription. This suggests BRD4 as a potential therapeutic target for patients with fibrotic complications.",
keywords = "Antifibrotic therapy, BET inhibitor, BRD4, Hepatic stellate cell, Liver fibrosis",
author = "Ning Ding and Nasun Hah and Yu, {Ruth T.} and Mara Sherman and Chris Benner and Mathias Leblanc and Mingxiao He and Christopher Liddle and Michael Downes and Evans, {Ronald M.}",
year = "2015",
month = "12",
day = "22",
doi = "10.1073/pnas.1522163112",
language = "English (US)",
volume = "112",
pages = "15713--15718",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "51",

}

TY - JOUR

T1 - BRD4 is a novel therapeutic target for liver fibrosis

AU - Ding, Ning

AU - Hah, Nasun

AU - Yu, Ruth T.

AU - Sherman, Mara

AU - Benner, Chris

AU - Leblanc, Mathias

AU - He, Mingxiao

AU - Liddle, Christopher

AU - Downes, Michael

AU - Evans, Ronald M.

PY - 2015/12/22

Y1 - 2015/12/22

N2 - Liver fibrosis is characterized by the persistent deposition of extracellular matrix components by hepatic stellate cell (HSC)-derived myofibroblasts. It is the histological manifestation of progressive, but reversible wound-healing processes. An unabated fibrotic response results in chronic liver disease and cirrhosis, a pathological precursor of hepatocellular carcinoma. We report here that JQ1, a small molecule inhibitor of bromodomain-containing protein 4(BRD4), a member of bromodomain and extraterminal (BET) proteins, abrogate cytokine-induced activation of HSCs. Cistromic analyses reveal that BRD4 is highly enriched at enhancers associated with genes involved in multiple profibrotic pathways, where BRD4 is colocalized with profibrotic transcription factors. Furthermore, we show that JQ1 is not only protective, but can reverse the fibrotic response in carbon tetrachloride-induced fibrosis in mouse models. Our results implicate that BRD4 can act as a global genomic regulator to direct the fibrotic response through its coordinated regulation of myofibroblast transcription. This suggests BRD4 as a potential therapeutic target for patients with fibrotic complications.

AB - Liver fibrosis is characterized by the persistent deposition of extracellular matrix components by hepatic stellate cell (HSC)-derived myofibroblasts. It is the histological manifestation of progressive, but reversible wound-healing processes. An unabated fibrotic response results in chronic liver disease and cirrhosis, a pathological precursor of hepatocellular carcinoma. We report here that JQ1, a small molecule inhibitor of bromodomain-containing protein 4(BRD4), a member of bromodomain and extraterminal (BET) proteins, abrogate cytokine-induced activation of HSCs. Cistromic analyses reveal that BRD4 is highly enriched at enhancers associated with genes involved in multiple profibrotic pathways, where BRD4 is colocalized with profibrotic transcription factors. Furthermore, we show that JQ1 is not only protective, but can reverse the fibrotic response in carbon tetrachloride-induced fibrosis in mouse models. Our results implicate that BRD4 can act as a global genomic regulator to direct the fibrotic response through its coordinated regulation of myofibroblast transcription. This suggests BRD4 as a potential therapeutic target for patients with fibrotic complications.

KW - Antifibrotic therapy

KW - BET inhibitor

KW - BRD4

KW - Hepatic stellate cell

KW - Liver fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84952683263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952683263&partnerID=8YFLogxK

U2 - 10.1073/pnas.1522163112

DO - 10.1073/pnas.1522163112

M3 - Article

C2 - 26644586

AN - SCOPUS:84952683263

VL - 112

SP - 15713

EP - 15718

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 51

ER -